Nanomedicine in Pulmonary Delivery

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2010 Jan 8

PMID 20054434

Citations 134

Authors

Heidi M Mansour

Yun-Seok Rhee

Xiao Wu

Affiliations

Soon will be listed here.

Abstract

The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.

Citing Articles

Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.

Fernandez-Garcia R, Fraguas-Sanchez A Pharmaceutics. 2025; 16(12.

PMID: 39771562 PMC: 11677881. DOI: 10.3390/pharmaceutics16121584.

Synergistic effect of curcumin and Piperine loaded Niosomal nanoparticles on acute pulmonary toxicity induced by Paraquat in mice.

Khederzadeh A, Ebrahimnejad P, Seyedabadi M, Babaei A, Talebpour Amiri F, Aslani N Toxicol Res (Camb). 2024; 13(6):tfae181.

PMID: 39507590 PMC: 11537766. DOI: 10.1093/toxres/tfae181.

The eATP/P2×7R Axis Drives Quantum Dot-Nanoparticle Induced Neutrophil Recruitment in the Pulmonary Microcirculation.

Li C, Liu Q, Han L, Zhang H, Immler R, Rathkolb B Adv Sci (Weinh). 2024; 11(45):e2404661.

PMID: 39364760 PMC: 11615809. DOI: 10.1002/advs.202404661.

Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery.

Mansour H, Muralidharan P, Hayes Jr D J Aerosol Med Pulm Drug Deliv. 2024; 37(4):202-218.

PMID: 39172256 PMC: 11465844. DOI: 10.1089/jamp.2024.29117.mk.

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.

Lei L, Pan W, Shou X, Shao Y, Ye S, Zhang J J Nanobiotechnology. 2024; 22(1):343.

PMID: 38890749 PMC: 11186260. DOI: 10.1186/s12951-024-02627-w.

References

Kichler A, Leborgne C, Coeytaux E, Danos O . Polyethylenimine-mediated gene delivery: a mechanistic study. J Gene Med. 2001; 3(2):135-44. DOI: 10.1002/jgm.173. View

Joshi M, Misra A . Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol. 2003; 30(3):153-6. DOI: 10.1046/j.1440-1681.2003.03813.x. View

Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q . Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008; 356(1-2):333-44. DOI: 10.1016/j.ijpharm.2008.01.008. View

Chollet P, Favrot M, Hurbin A, Coll J . Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med. 2002; 4(1):84-91. DOI: 10.1002/jgm.237. View

Barry P, OCallaghan C . An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol. 1999; 104(6):1168-73. DOI: 10.1016/s0091-6749(99)70009-6. View

Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W . Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm. 2008; 357(1-2):286-94. DOI: 10.1016/j.ijpharm.2008.01.046. View

Bai S, Thomas C, Ahsan F . Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci. 2007; 96(8):2090-106. DOI: 10.1002/jps.20849. View

Pandey R, Sharma A, Zahoor A, Sharma S, Khuller G, Prasad B . Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003; 52(6):981-6. DOI: 10.1093/jac/dkg477. View

Videira M, Gano L, Santos C, Neves M, Almeida A . Lymphatic uptake of lipid nanoparticles following endotracheal administration. J Microencapsul. 2007; 23(8):855-62. DOI: 10.1080/02652040600788221. View

10.

Chadwick S, Kingston H, Stern M, Cook R, OConnor B, Lukasson M . Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther. 1998; 4(9):937-42. DOI: 10.1038/sj.gt.3300481. View

11.

Lynch J, Behan N, Birkinshaw C . Factors controlling particle size during nebulization of DNA-polycation complexes. J Aerosol Med. 2007; 20(3):257-68. DOI: 10.1089/jam.2007.0605. View

12.

de Semir D, Petriz J, Avinyo A, Larriba S, Nunes V, Casals T . Non-viral vector-mediated uptake, distribution, and stability of chimeraplasts in human airway epithelial cells. J Gene Med. 2002; 4(3):308-22. DOI: 10.1002/jgm.264. View

13.

Ahmad Z, Zahoor A, Sharma S, Khuller G . Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005; 26(4):298-303. DOI: 10.1016/j.ijantimicag.2005.07.012. View

14.

Groneberg D, Witt C, Wagner U, Chung K, Fischer A . Fundamentals of pulmonary drug delivery. Respir Med. 2003; 97(4):382-7. DOI: 10.1053/rmed.2002.1457. View

15.

Shahiwala A, Misra A . A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: a technical note. AAPS PharmSciTech. 2005; 6(3):E482-6. PMC: 2750394. DOI: 10.1208/pt060360. View

16.

Manford F, Tronde A, Jeppsson A, Patel N, Johansson F, Forbes B . Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. Eur J Pharm Sci. 2005; 26(5):414-20. DOI: 10.1016/j.ejps.2005.07.010. View

17.

Wernig K, Griesbacher M, Andreae F, Hajos F, Wagner J, Mosgoeller W . Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release. 2008; 130(2):192-8. DOI: 10.1016/j.jconrel.2008.06.005. View

18.

Bai S, Ahsan F . Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res. 2008; 26(3):539-48. DOI: 10.1007/s11095-008-9769-y. View

19.

Maa Y, Nguyen P, Sweeney T, Shire S, Hsu C . Protein inhalation powders: spray drying vs spray freeze drying. Pharm Res. 1999; 16(2):249-54. DOI: 10.1023/a:1018828425184. View

20.

Khanna C, Anderson P, Hasz D, Katsanis E, Neville M, Klausner J . Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer. 1997; 79(7):1409-21. DOI: 10.1002/(sici)1097-0142(19970401)79:7<1409::aid-cncr19>3.0.co;2-3. View